Antibodies: Difference between revisions
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
*How do you culture antibodies? Via hybridomas - [https://en.wikipedia.org/wiki/Hybridoma_technology] | *How do you culture antibodies? Via hybridomas - [https://en.wikipedia.org/wiki/Hybridoma_technology] | ||
= | =Companies Working on It= | ||
*GigaGen - [https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies] - ''uses single-cell sequencing to “capture and recreate” whole libraries of antibodies from recovered COVID-19 patients. The company can then choose which of those antibodies to turn into recombinant polyclonal antibody treatments'' | *GigaGen - [https://www.fiercebiotech.com/biotech/gigagen-jumps-into-covid-19-arena-polyclonal-antibodies] - ''uses single-cell sequencing to “capture and recreate” whole libraries of antibodies from recovered COVID-19 patients. The company can then choose which of those antibodies to turn into recombinant polyclonal antibody treatments'' | ||
=Definitions= | =Definitions= | ||
*Antigen. [https://www.google.com/search?q=example+of+an+antigen&oq=example+of+an+antigen&aqs=chrome..69i57j0l5.6058j1j7&client=ubuntu&sourceid=chrome&ie=UTF-8] - ex: a virus. | *Antigen. [https://www.google.com/search?q=example+of+an+antigen&oq=example+of+an+antigen&aqs=chrome..69i57j0l5.6058j1j7&client=ubuntu&sourceid=chrome&ie=UTF-8] - ex: a virus. | ||
*Recombinant DNA - genetic engineering of DNA that does not yet exist in nature - [https://en.wikipedia.org/wiki/Recombinant_DNA] | *Recombinant DNA - genetic engineering of DNA that does not yet exist in nature - [https://en.wikipedia.org/wiki/Recombinant_DNA] | ||
Revision as of 02:29, 6 April 2020
- Antibodies are blood proteins that kill cellular intruders (disease) - [1]
- How do you culture antibodies? Via hybridomas - [2]
Companies Working on It
- GigaGen - [3] - uses single-cell sequencing to “capture and recreate” whole libraries of antibodies from recovered COVID-19 patients. The company can then choose which of those antibodies to turn into recombinant polyclonal antibody treatments